Statins Litigation Summary



Lawsuits against Pfizer were recently certified into MDL 2502 before U.S. District Judge Richard M. Gergel in South Carolina. Plaintiffs allege that the LIPITOR® (atorvastatin calcium) warning label used medical jargon that would not be considered common knowledge and furthermore did not sufficiently warn users of a link to Type-II diabetes.

The Women’s Health Initiative (WHI) released a study in 2012 showing significant risk to post-menopausal women of developing Type-II diabetes shortly after use. As one of the most profitable and widely prescribed drugs of the last two decades, many plaintiffs are expected to come forward with claims.

Individual CRESTOR® (rosuvastatin calcium) lawsuits allege numerous injuries including Kidney Damage, Liver Damage, Rhabdomyolysis (muscle damage), Sudden Cardiac Death, and the same claim of a link between Type-II diabetes and post-menopausal women.

Topics:  Complex Litigation, Crestor, Healthcare, Lipitor, Pfizer, Pharmaceutical, Warning Labels

Published In: Personal Injury Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Case Funding Inc. | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »